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Abstract: Current practice guidelines for the treatment of COPD recommend the use of com-
bined inhaled corticosteroids and long-acting bronchodilators in severe and very severe patients 
(GOLD stages III and IV). The aim of this study was to evaluate, through a simulation model, 
the economic consequences of this recommendation in Italy. We developed a cost-effectiveness 
analysis (CEA) on ﬁ  ve alternative therapeutic strategies (salmeterol/ﬂ  uticasone, SF; formoterol/
budesonide, FB; salmeterol alone, S; ﬂ  uticasone alone, F; control, C). Published data on the 
Italian COPD population and efﬁ  cacy data from international reference trials were ﬁ  tted in a 
disease progression model based on a Markov chain representing severity stages and death. 
The yearly total direct costs of treating COPD patients in Italy was estimated at approximately 
€7 billion, with a mean cost per patient per year of around €2450. Mean survival of the cohort 
is 11.5 years. The C and F strategies were dominated (ie, are associated with worse outcomes 
and higher costs) by all alternatives. SF and FB were the most effective strategies, with a slight 
clinical superiority of SF, but they were also marginally more expensive than S. Incremental 
cost-effectiveness of SF vs S was €679.5 per avoided exacerbation and €3.3 per symptom-free 
day. Compared with current practice, the recommended use of combined inhaled corticosteroids 
and long-acting bronchodilators for severe and very severe COPD patients has the potential for 
improving clinical outcomes without increasing healthcare costs.
Keywords: severe COPD, pharmacoeconomics, Markov chain, inhaled corticosteroids, inhaled 
bronchodilators, cost-effectiveness
Introduction
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in 
the world (WHO 2000) and it is ranked among the ﬁ  rst causes of disability in developed 
countries like Italy. COPD in Italy is a disease with substantial social costs as it ranks 
7th by number of hospital admissions and 4th by number of hospital days.
Exacerbation is the main cause of hospital admission in COPD patients. Exacerba-
tion implies a substantial impairment of patient respiratory ability and quality of life 
and can even lead to death.
It has been demonstrated that only smoking cessation can produce a relative 
slowdown in the chronic course of the disease, while pharmaceutical therapies aim to 
improve patients’ quality of life by reducing exacerbation frequency and severity. 
The Global Initiative for Chronic Lung Disease (GOLD) was established in 1997. 
Its goals are to increase awareness of COPD and decrease mortality and morbidity 
from the disease. 
The GOLD 2004 guideline (GOLD 2004) classiﬁ  es disease severity in 4 stages 
based on chronic symptoms, forced expiratory volume in 1 second (FEV1), and forced 
vital capacity (FVC).International Journal of COPD 2007:2(2) 170
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This pragmatic staging approach aims to simplify 
practical patient management and offer some gen-
eral indications for pharmacotherapeutic choice. Risk 
factor avoidance and inﬂ  uenza vaccination, which can 
prevent serious illness and complication onset, are baseline 
recommendations in all stages of patient treatment. At 
stage I, bronchodilators are generally prescribed on an 
as-needed basis for relief of persistent, or worsening, 
symptoms. The most commonly used bronchodilator drugs 
include ß2-agonists, anticholinergics, and methylxanthines. 
At stage II, GOLD guidelines recommend the addition of 
pulmonary rehabilitation and regular treatment with one or 
more long-acting bronchodilators. Pulmonary rehabilita-
tion aims at resolving a range of nonpulmonary problems 
including social isolation, altered mood states (especially 
depression), muscle wasting, and weight loss. The addition 
of regular treatment with inhaled glucocorticosteroids is 
appropriate for symptomatic COPD patients with an FEV1 
<50% predicted (stage III and stage IV). Combined inhaled 
glucocorticosteroids and long-acting ß2-agonists are more 
effective than the individual components; according with 
GOLD judgments, combining drugs with different mecha-
nisms and durations of action might increase the degree 
of bronchodilation with equivalent or fewer side-effects. 
Long-term oxygen therapy is generally added in stage IV, 
while other pharmacological treatments (such as antioxi-
dants and mucolytic agents) are frequently used as adjuvant 
therapy. 
The economic consequences of the adoption of the 
GOLD strategy, especially the use of inhaled glucocor-
ticosteroids combined with long-acting ß2-agonists, for 
the whole Italian COPD patient population have not been 
assessed yet. 
In the absence of “real” data from specific trial 
or observational studies, it is a quite well established 
practice to build analytical models that simulate disease 
dynamics and infer clinical and economic outcomes of 
competing treatment strategies. In particular, for chronic 
diseases such as COPD, where the horizon of the analysis 
spans over the whole patient’s lifetime, a modeling 
approach for economic evaluation could easily be the 
only choice. Trials of the necessary size and duration 
would be unrealistic. 
The aim of the present study is to evaluate, through 
a simulation model, the clinical and economic consequences 
of the implementation of GOLD 2004 guidelines for severe 
and very severe COPD patients in Italy.
Material and methods
We developed a cost-effectiveness analysis (CEA) on the use 
of combined inhaled glucocorticosteroids and long-acting 
ß2-agonists to evaluate the relative pharmacoeconomic per-
formance of the two available products. We then compared 
a combined treatment with a single inhaled corticosteroid 
and with a single long-acting bronchodilator. The control in 
each case was a standard treatment.
The CEA is the typical economic evaluation that should 
be performed when comparing 2 or more therapeutic alter-
natives whose clinic efﬁ  cacy is not equivalent (Drummond 
et al 1997). In this analysis, both the costs and the health 
consequences of the alternatives are examined. The direct 
comparison between two alternatives is obtained through 
the incremental cost effectiveness ratio (ICER). Comparing 
strategy A with strategy B, the ICER value represents the 
relative increment of cost at which a relative unitary incre-
ment of beneﬁ  t could be obtained. If we indicate the cost 
of the two alternatives by CA and CB, and the beneﬁ  ts (for 
instance, life years saved, hospitalization avoided, …) by BA 
and BB this gives Eq. (1)
  ICER
CC
BB
AB
AB
=
−
−  (1)
In this study the costs and beneﬁ  ts were evaluated with a 
simulation model. This was designed as a Markov chain 
which simulates the disease course and consequences 
under a speciﬁ  c treatment for a given cohort of patients. All 
calculations were run in MS Excel. 
The ﬁ  ve therapeutic alternatives considered were:
•  Control (C): no change with respect to the standard 
therapy already in use by the patient;
•  Salmeterol/ﬂ  uticasone (SF): use of combined salme-
terol/ﬂ  uticasone 50/500 μg bid in GOLD stages III and 
IV patients in addition to the standard therapy already in 
use;
•  Formoterol/budesonide (FB): use of combined formoter-
ol/budesonide 2 × 160/4.5 μg bid in GOLD stages III and 
IV patients in addition to the standard therapy already in 
use;
•  Fluticasone (F): use of ﬂ  uticasone 500 μg bid in GOLD 
stages III and IV patients in addition to the standard 
therapy already in use;
•  Salmeterol (S): use of salmeterol 50 μg bid in GOLD 
stages III and IV patients in addition to the standard 
therapy already in use.International Journal of COPD 2007:2(2) 171
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Model structure
The Markov chain comprised 5 health states, representing 4 
COPD severity stages – stage I mild, stage II moderate, stage 
III severe, and stage IV very severe – and death (Figure 1). 
The simulation cycle lasts 1 year. During every cycle 
each patient in the cohort has the possibility of progressing 
to the next worse health state, remaining in the current state, 
or dying. This progression is regulated by the transition prob-
abilities among states.
Due to the choice of a relatively short cycle duration no 
direct transition to further worse states (ie, from stage I to 
stage III) is allowed. This means that we have only transitions 
between adjacent severity states. Moreover, no regression of 
the disease (ie, leftward transition) is allowed.
Initial population
In our study the cohort that populates the model at the 
beginning of the simulation is deﬁ  ned to represent the 
whole Italian population of COPD patients. Several 
epidemiological studies have attempted to measure the 
prevalence of respiratory symptoms and COPD among 
the general Italian population (Viegi et al 1988, 2001; 
Stang et al 2000; ISTAT 2001; De Marco et al 2004). An 
international study (De Marco et al 2004) reported a 1.3% 
COPD prevalence in Italy for people aged 20–44 years. An 
Italian study (Viegi et al 2001) reported a 6% prevalence 
in the population aged 46–55 and 11% in the population 
aged 56–65 years. A multi-purpose study from the Italian 
Statistics Institute (ISTAT 2001) reported a 14.1% preva-
lence in the elderly population (over 65 years).
The application of these data to the general Italian 
population (from ISTAT 1999–2000) leads to an estimate of 
about 2.9 million COPD patients. This value well compares 
with the results of a smoking rates-based disease model 
(Stang et al 2000) which estimated that in Italy 2.6 million 
men and women aged 45–70 years suffer from diagnosed 
or undiagnosed COPD. In order to populate the health 
states, the whole cohort had to be split into severity stages. 
Unfortunately, no study presenting COPD prevalence by 
GOLD severity stages is currently available for Italy. The 
closest pertinent data available on published literature are 
related to US and UK COPD patients, as reported in the 
2004 ERS Congress (Price et al 2004) (Table 1). We used 
the values published in this study to arrange the initial 
model population (42% stage I, 41% stage II, 13% stage 
III, and 4% stage IV).
Model health states were characterized by an average 
FEV1 value and an average exacerbation per patient per 
year value. The set of FEV1 values by state was obtained 
from an Italian population study (SaRA – Salute Respi-
ratoria nell’Anziano) (Antonelli-Incalzi et al 2003). The 
number of exacerbations by severity stage is a set of 
values hard to find in the literature, mainly because the 
definition of exacerbation itself is not standard among 
authors. We made an estimate via an adaptation of data 
reported in the ISOLDE (Inhaled Steroids in Obstructive 
Lung Disease in Europe) (Burge and Wezicha 2003) 
study to GOLD severity stages, with the use of the 
NHANES/Hankinson equation (Hankinson et al 1999) 
for predicted FEV1.
Stage I
Mild
Stage II 
Moderate
Stage III 
Severe
Stage IV
Very 
Severe
Death
Figure 1 Markov chain structure.   Arrows represent the possible pathways of the disease course.International Journal of COPD 2007:2(2) 172
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Transition probabilities
For each disease stage, the probability of progressing to 
the next worse health state was calculated from the average 
pulmonary capacity reduction of COPD patients (Fletcher 
et al 1976) and predicted values of FEV1 (Crapo and Morris 
1981; Crap et al 1981, 1982).
The transition probability to the death state was obtained 
by applying a stage-speciﬁ  c relative risk (RR) to the mortality 
rates of the general Italian population (ISTAT 2003). These 
RRs were calculated in order to ﬁ  t the 4-year survival ratios 
presented for each disease severity stage in a 2002 study 
(Domingo-Salvany et al 2002), which showed a strong 
relationship between mortality and FEV1.
Outcomes
Treatment efﬁ  cacy for the SF, S, and F alternatives was derived 
from the reference trial (Calverley et al 2003) of the salmeterol/
ﬂ  uticasone combination (which compared the combination 
with the two single components and placebo). The efﬁ  cacy for 
the FB alternative was derived from the reference trial (Szaf-
ranski et al 2003) of the formoterol/budesonide combination. 
The two international randomized controlled trials (RCTs) 
have a substantially overlapping protocol. 
Another international RCT (Calverley et al 2003) with 
similar results, but with a slight protocol difference due to the 
presence of a run-in phase, was discarded in order to obtain 
the maximum possible source homogeneity. 
The application of international RCT ﬁ  ndings to an Italian 
setting was validated by a smaller Italian study (Dal Negro 
et al 2003a) which shows very similar results.
All these studies conﬁ  rm the judgment expressed by 
the GOLD Panel that none of the existing medications 
for COPD can modify the long-term decline in lung func-
tion. Therefore the main aim of COPD pharmacotherapy 
is to control symptoms and exacerbations severity and 
frequency.
Consequently the annual average exacerbation number 
and percentage of symptom-free days per patient were con-
sidered as outcomes for CEA.
Costs and cost perspective
Model costs were calculated via an adaptation of the ICE 
(Italian Costs for Exacerbations in COPD) study (Lucioni et 
al 2005) and from Dal Negro et al (2003b), and are classiﬁ  ed 
as direct and indirect costs for each disease stage.
Direct costs take into account hospitalizations, medical 
visits, and examinations, pharmaceutical treatments (differ-
ent from SF, FB, S, or F), oxygen therapy, lung ventilation, 
and rehabilitative therapy.
Indirect costs account for lost productivity of the patient 
and ﬁ  rst degree relatives.
The ICE study classiﬁ  ed both direct and indirect costs 
in two parts, one caused directly by exacerbations and one 
independent of them. 
This classiﬁ  cation let us calculate the cost per exacerba-
tion for each disease stage (Table 3)
The pharmaceutical cost for the active treatment (SF, 
FB, S, or F) should be added to the direct exacerbation-
independent cost. In Italy this cost is paid by the National 
Health Service.
Table 1 Model initial population characteristics
  I: Mild  II: Moderate  III: Severe  IV: Very severe  Total  Source
% population   42%  41%  13%  4%  100%  Price et al 2004
Initial population  1,216,444  1,187,481  376,518  115,852  2,896,296 
          
FEV1 (% predicted)  89.80%  63.70%  40.00%  26.20%    Antonelli-Incalzi et al 2003
Exacerbations/patient/year  0  0.8  1.8  2.6    Authors’ estimate from 
            ISOLDE (Hankinson et al
            1999; Burge and Wedzicha  
           2003)
Table 2 Main outcomes. Derived from Calverley et al (2003) and Szafransky et al (2003)
  C  SF (Calverley)  FB (Szafranski)  S (Calverley)  F (Calverley)
Exacerbation RR (vs placebo)    0.70  0.76  0.80  0.81
Symptom-free days   0%  14%  12%  3%  2%
Abbreviations: C, control; F, ﬂ  uticasone alone; FB, formoterol/budesonide; RR, relative risk; S, salmeterol alone; SF, salmeterol/ﬂ  uticasone.International Journal of COPD 2007:2(2) 173
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Different cost perspectives are adopted in CEA:
•  Patient perspective: in this case only indirect costs were 
taken into account;
•  Italian National Health Service perspective: only direct 
costs were taken into account; 
•  Societal perspective: direct plus indirect costs were taken 
into account.
Results
The time horizon of the simulation was 1, 5, 10 years, and life-
long, which means that the model iteration was stopped when the 
whole cohort reaches the death state. At the end of the simulation 
the average cohort survival was 11.5 years (Table 4).
The total yearly direct costs of managing COPD patients 
in Italy were estimated at approximately €7 billion, with a 
mean cost per patient per year of around €2450.
The indirect costs results were scarcely signiﬁ  cant com-
pared with the direct costs, as they represent on average 
less than 2% of the total. Therefore CEA is performed only 
from the perspective of the Italian National Health Service, 
in which only direct costs are taken into account.
All strategies appeared to be dominant (ie, give a better 
outcome at a smaller cost) with respect to C, except for S which 
was slightly more costly. SF and FB were the most effective 
strategies, with SF having a slight clinical advantage, but they 
were also marginally more expensive than S (Figure 2). 
The ICER was calculated for these two alternatives with 
respect to S. The ICER value here represents the amount that 
should be paid to obtain a unit increase in outcome (ie, one 
exacerbation avoided or a symptom-free day gained) with 
the adoption of a more efﬁ  cient and more expensive strategy 
(SF or FB vs S) (Table 5).
Sensitivity analysis
One-way sensitivity analyses on the main model parameters 
were performed in order to assess the robustness of the results 
obtained from the model. The SF vs C case (with exacerba-
tion reduction as an outcome) is presented here. All other 
possible combinations show a similar behavior. 
Dominancy of the SF strategy could be lost mainly due to:
•  Reduction of the average initial number of exacerbations 
per patient per year;
•  Reduction of treatment efﬁ  cacy in terms of exacerbations 
reduction;
•  Reduction of hospitalization costs;
•  Increase of treatment pharmaceutical cost. 
This means that as a consequence of one of these varia-
tions the SF strategy could become more costly than C. The 
threshold value gives the point where the differential cost 
between SF and C strategies equals zero (Table 6). 
Discussion
Attention to COPD is constantly increasing worldwide 
because its high prevalence, morbidity, and mortality 
represent a challenging problem for all healthcare systems. 
The burden of COPD, measured as its impact on patients’ 
Table 3 Direct and indirect costs. Derived from Lucioni et al (2005) and Dal Negro et al (2003b)
Costs (€/patient/year)
  Stage I  Stage II  Stage III  Stage IV
Direct cost independent of exacerbation  527.48  918.38  1592.59  3586.18
Direct cost per exacerbation    1219.46  1475.87  2637.33
Indirect cost independent of exacerbation    15.77  21.97  43.71
Indirect cost per exacerbation    27.81  38.76  77.10
Table 4 Model outcomes and costs (€) at the end of a life-long simulation (average values per patient)
Strategy  Exacerbation   Symptom-  Direct cost  Indirect   Direct + 
  number  free days    cost  Indirect  
        cost
C 12.04  0  34,632.09    715.74    35,347.83
S 10.07  55  33,369.28    619.87  33,989.15
F 10.14  37  34,754.38    623.55    35,377.93
SF 9.09  257  34,037.71    571.93  34,609.64
FB 9.66  220  33,944.51    599.73    34,544.25
Abbreviations: C, control; F, ﬂ  uticasone alone; FB, formoterol/budesonide; S, salmeterol alone; SF, salmeterol/ﬂ  uticasone.International Journal of COPD 2007:2(2) 174
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symptoms and quality of life and the corresponding use of 
healthcare resources, is still a major aspect of the disease.
For these reasons healthcare decision makers, before 
deciding which strategies should be preferred, need to 
improve their understanding of the concept of good value for 
money, in order to control the disease and reduce the huge 
costs required to meet patients’ needs.
It is now well established that the main proportion of 
COPD costs depends on the clinically uncontrolled disease 
and on its high exacerbation rate, frequently leading to the 
patients’ hospitalization.
Recommendations to treat COPD according to the most 
accepted guidelines have been disseminated over recent 
years even though COPD still remains under-diagnosed 
Figure 2 Cost and outcomes resulting from 1, 5, and 10 years, and life-long time horizon simulation. 
Abbreviations: C, control; F, ﬂ  uticasone alone; FB, formoterol/budesonide; S, salmeterol alone; SF, salmeterol/ﬂ  uticasone.
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Table 5 Incremental cost effectiveness ratio (ICER) calculation with respect to the less expensive strategy (S)
     Exacerbations per   Symptom-free days   Direct cost per 
    patient  per patient  patient (€)
SF vs S  Difference   0.98  202  668.43 
  ICER   679.55 (€/exacerbation)  3.31 (€/symptom-free day)   
FB vs S  Difference   0.41  165  575.23 
 ICER  1392.38(€/exacerbation)  3.48(€/symptom-free  day)   
Abbreviations: C, control; F, ﬂ  uticasone alone; FB, formoterol/budesonide; RR, relative risk; S, salmeterol alone; SF, salmeterol/ﬂ  uticasone.
Table 6 Base case and threshold values of model parameters 
that can cause strategy dominancy loss more rapidly
Parameter Base  value  Threshold 
   value
Average initial population number  0.67  0.59
of exacerbations/patient/year
Relative risk exacerbations  0.700  0.734
Hospitalization costs  €1862.00   €1584.00 
Treatment pharmaceutical cost  €81.43   €91.28 
and under-treated worldwide. Obviously, more severe 
degrees of COPD have received most attention both in 
terms of monitoring of clinical outcomes and in assessing 
the economic value of therapeutic interventions, although 
the effects of guideline recommendations have been inves-
tigated in terms of pharmacoeconomic convenience only 
episodically.
The main scope of this study was to evaluate the clinical 
and economic consequences of implementation of GOLD 
guidelines for severe and very severe COPD patients in 
Italy. The affordability of its widespread application, as 
well as the relative pharmacoeconomic performance of the 
available options for severe and very severe COPD, were 
investigated. Although the clinical efﬁ  cacy of the suggested 
approach is widely accepted, the economic consequences and 
National Health Service budget impact have not yet been 
well assessed. To contribute to the understanding of this 
point, we designed a pharmacoeconomic analytical model 
which combines clinical data from international RCTs with 
local economic studies and demographic data. The main 
limit of this study is the model itself. Analytical models 
necessarily are a simpliﬁ  cation and schematization of the 
real process they represent. But modeling is often the only 
viable approach to economic evaluation, because for chronic 
disease trials of the necessary size and duration would be 
unrealistic. We should point out the frequent need in our 
model for assumptions mainly because of the heterogeneity 
of the different sources of information and the substantial 
scarcity of Italian data.
There is a good general consensus that combining 
medications of different pharmacological classes represents 
a much more convenient strategy in COPD, particularly for 
severe or very severe disease. Additional effects have in fact 
been proven both in functional and in clinical terms under 
these conditions. In particular, health status, quality of life, 
and exacerbations represent the most affected outcomes 
in more severe COPD (basal FEV1 <50% predicted) when 
treated with combined long-acting β2-agonists and inhaled 
corticosteroids over time. These data highlighted the favo-
rable therapeutic performance of this particular strategy, 
thus suggesting that healthcare costs would be also affected 
positively.
In agreement with the GOLD recommendation, the 
therapeutic strategies investigated the use of two dif-
ferent combined inhaled corticosteroids and long-acting 
bronchodilators in comparison with a single inhaled 
corticosteroid, a single long-acting bronchodilator, and 
control.
Results from the model showed that the recommended 
use of combined inhaled corticosteroids and long-acting 
bronchodilators for severe and very severe COPD patient 
treatment, compared with current practice, had the po-
tential to improve clinical outcomes, and consequently 
patients quality of life, without increasing healthcare 
costs. The same conclusion was drawn in recent studies 
(Gagnon et al 2005; Lofdahl et al 2005; Spencer et al 
2005), based on a similar modeling approach, developed 
for the US, Canadian, and Swedish healthcare systems, 
respectively.
This conclusion seems relevant not only from the patient’s 
perspective (such as improvement of clinical conditions) but 
also from a societal perspective. These data conﬁ  rm that it is 
possible to improve substantially the health status of severe 
and very severe COPD patients without further increasing 
social costs.International Journal of COPD 2007:2(2) 176
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